Design Therapeutics (DSGN) EBITDA (2020 - 2026)

Design Therapeutics has disclosed EBITDA across 7 years of filings, most recently posting -$19.7 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$19.7 million, down 11.08% year-over-year; the trailing twelve-month figure through Mar 2026 was -$78.8 million (down 35.35% YoY), and the FY2025 annual result was -$79.5 million, down 27.39% from the prior year.
• EBITDA came in at -$19.7 million for Q1 2026 at Design Therapeutics, down from -$18.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$10.5 million in Q4 2023 to a low of -$21.6 million in Q2 2025.
• The 5-year median for EBITDA is -$16.8 million (2022), against an average of -$16.4 million.
• Across the five-year window, EBITDA sank 153.05% in 2022 and soared 40.65% in 2024, its largest moves.
• Design Therapeutics' EBITDA stood at -$16.8 million in 2022, then soared by 37.65% to -$10.5 million in 2023, then tumbled by 59.04% to -$16.7 million in 2024, then declined by 8.84% to -$18.2 million in 2025, then declined by 8.46% to -$19.7 million in 2026.
• The last three EBITDA figures came in at -$19.7 million (Q1 2026), -$18.2 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.